新天药业 (002873)

Guiyang Xintian Pharmaceutical Co.,Ltd.

ASZ

Tags

Generic DrugsImmunotherapyInnovative DrugsPharmaceutical ManufacturingMicro Cap StocksNew Private Equity HoldingsHepatitis ConceptShareholder Reduction

K-Line Chart

No K-line data

Stock Details

1. Key Indicators

  • Total Shares(W): 24410.38
  • Circulating A-Shares(W): 23866.88
  • Earnings Per Share(RMB): 0.0663
  • Net Assets Per Share(RMB): 5.1753
  • Operating Revenue(W RMB): 55863.30
  • Total Profit(W RMB): 1667.16
  • Net Profit Attributable to Parent(W RMB): 1618.09
  • Net Profit Growth Rate(%): -73.47
  • Weighted Return on Equity(%): 1.35
  • Operating Cash Flow Per Share(RMB): 0.4750
  • Undistributed Profit Per Share(RMB): 2.3165
  • Capital Reserve Per Share(RMB): 1.1567

2. Main Business

The main business covers:

  • R&D, production, and sales of new Chinese patent medicines

3. Company Basic Information

  • Company Name: Guiyang Xintian Pharmaceutical Co., Ltd.
  • Listing Date: 2017-05-19
  • Industry: Pharmaceutical Manufacturing
  • Address: No. 3 Gaoxin North Road, Wudang District, Guiyang City, Guizhou Province
  • Website: www.gyxtyy.com
  • Company Profile: According to the approval document Qian Fu Han [2001] No. 661 from the Guizhou Provincial People's Government, the company was established by converting the total audited net assets of RMB 40,573,340.31 as of August 31, 2001 (as per the audit report Shen Hua [2001] Shen Zi No. 398 issued by Shenzhen Dahua Tiancheng Certified Public Accountants) into 40.57 million shares at a 1:1 ratio, with the remaining RMB 3,340.31 credited to capital reserve. The company was transformed into Guiyang Xintian Pharmaceutical Co., Ltd. and obtained the Business License with registration number 5200001204533 on December 30, 2001.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Shanghai Xintian Zhiyao Biotechnology Co., Ltd. Corporate Legal Person 7548.56 31.63
2 Morgan Stanley Health Industry Hybrid Securities Investment Fund A Class Fund 201.91 0.85
3 Guiyang Kaiyuan Biological Resources Development Co., Ltd. Corporate Legal Person 166.97 0.70
4 CITIC Securities Asset Management (Hong Kong) Limited - Client Funds Asset Management Plan 111.12 0.47
5 ChinaAMC CSI Traditional Chinese Medicine ETF Fund 105.97 0.44
6 Shanghai Yinye Investment Co., Ltd. - Yinye - Gongyu Theme Selection Phase 2 Private Securities Investment Fund Private Securities Investment Fund 100.00 0.42
7 Goldman Sachs & Co. LLC QFII 67.24 0.28

5. Concept Sectors

  • Immunotherapy
  • Generic Drugs
  • Hepatitis Concept
  • Innovative Drugs
  • Micro-Cap Stocks
  • Shareholder Reduction
  • New Private Placement

Remarks

  • Data update date: 2026-01-01
  • Data source: Public Market Information